Sharon Benzeno, Chief Commercial Officer at Imm Med, sold Adaptive Biotechnologies Corp ($ADPT) shares on the open market three times in the last year, totaling about $10.4 million. Her most recent sale occurred on December 4, 2025. These sales rank her 1092nd among 11,678 individual insiders by total value sold, compared to an average of $8.6 million per insider across about 6.4 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 63103 | $13.17 | 272,751.0000 | 163,162,107 | 18.79% | 0.04% |
| March 4, 2026 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Common Stock | 39063 | $0.00 | 335,854.0000 | 163,162,107 | 13.16% | 0.02% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 4290 | $0.00 | 12,871.0000 | 163,162,107 | 25.00% | 0.00% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 12604 | $16.85 | 296,791.0000 | 163,162,107 | 4.07% | 0.01% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 4157 | $3.99 | 309,395.0000 | 163,162,107 | 1.36% | 0.00% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 4157 | $0.00 | 112,247.0000 | 163,162,107 | 3.57% | 0.00% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 4157 | $0.00 | 62,360.0000 | 163,162,107 | 6.25% | 0.00% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 4290 | $12.14 | 301,081.0000 | 163,162,107 | 1.45% | 0.00% |
| Dec. 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 4157 | $8.46 | 305,238.0000 | 163,162,107 | 1.38% | 0.00% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 83145 | $3.99 | 605,268.0000 | 163,162,107 | 15.92% | 0.05% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 308477 | $16.91 | 296,791.0000 | 163,162,107 | 50.97% | 0.19% |
| Nov. 20, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 133032 | $0.00 | 66,517.0000 | 163,162,107 | 66.67% | 0.08% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 834 | $0.00 | 0.0000 | 163,162,107 | 100.00% | 0.00% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 20834 | $0.00 | 0.0000 | 163,162,107 | 100.00% | 0.01% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 49480 | $0.00 | 0.0000 | 163,162,107 | 100.00% | 0.03% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 34375 | $0.00 | 0.0000 | 163,162,107 | 100.00% | 0.02% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 119809 | $0.00 | 17,161.0000 | 163,162,107 | 87.47% | 0.07% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 83145 | $0.00 | 116,404.0000 | 163,162,107 | 41.67% | 0.05% |
| Nov. 20, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Stock Option (right to buy) | 68961 | $0.00 | 136,970.0000 | 163,162,107 | 33.49% | 0.04% |
| Nov. 20, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 133032 | $8.46 | 525,755.0000 | 163,162,107 | 33.87% | 0.08% |
| Nov. 20, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 68961 | $12.14 | 594,716.0000 | 163,162,107 | 13.12% | 0.04% |
| Nov. 20, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 297925 | $16.54 | 296,791.0000 | 163,162,107 | 50.10% | 0.18% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 834 | $6.27 | 297,625.0000 | 163,162,107 | 0.28% | 0.00% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 20834 | $6.55 | 318,459.0000 | 163,162,107 | 7.00% | 0.01% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 49480 | $6.55 | 367,939.0000 | 163,162,107 | 15.54% | 0.03% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 34375 | $7.27 | 402,314.0000 | 163,162,107 | 9.34% | 0.02% |
| Nov. 21, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | M | Common Stock | 119809 | $12.14 | 522,123.0000 | 163,162,107 | 29.78% | 0.07% |
| March 5, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 41600 | $6.98 | 395,788.0000 | 147,101,648 | 9.51% | 0.03% |
| March 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Stock Option (right to buy) | 165027 | $0.00 | 165,027.0000 | 147,101,648 | 9999.99% | 0.11% |
| March 5, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 3065 | $6.99 | 392,723.0000 | 147,101,648 | 0.77% | 0.00% |
| March 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Common Stock | 109973 | $0.00 | 437,388.0000 | 147,101,648 | 33.59% | 0.07% |
| March 5, 2024 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 18644 | $3.44 | 327,415.0000 | 144,383,294 | 5.39% | 0.01% |
| March 4, 2024 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Stock Option (right to buy) | 199549 | $0.00 | 199,549.0000 | 144,383,294 | 9999.99% | 0.14% |
| March 5, 2024 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 10746 | $3.43 | 346,059.0000 | 144,383,294 | 3.01% | 0.01% |
| March 4, 2024 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Common Stock | 132979 | $0.00 | 356,805.0000 | 144,383,294 | 59.41% | 0.09% |
| March 6, 2023 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | S | Common Stock | 11749 | $8.57 | 223,826.0000 | 142,515,917 | 4.99% | 0.01% |
| March 6, 2023 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Common Stock | 132979 | $0.00 | 235,575.0000 | 142,515,917 | 129.61% | 0.09% |
| March 6, 2023 | Adaptive Biotechnologies Corp | $ADPT | BENZENO SHARON | Chief Commercial Ofc Imm Med | A | Stock Option (right to buy) | 199549 | $0.00 | 199,549.0000 | 142,515,917 | 9999.99% | 0.14% |